Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial | Zendy

Catherine Hanna | Zendy; Kathreena M. Kurian | Zendy; Karin Williams | Zendy; Colin Watts | Zendy; Alan Jackson | Zendy; Ross Carruthers | Zendy; Karen Strathdee | Zendy; Garth Cruickshank | Zendy; Laurence Dunn | Zendy; Sara Erridge | Zendy; Lisa Godfrey | Zendy; Sarah Jefferies | Zendy; Catherine McBain | Zendy; Rebecca Sleigh | Zendy; Alex McCormick | Zendy; Marc Pittman | Zendy; Sarah Halford | Zendy; Anthony J. Chalmers | Zendy

Open Access

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

Author(s) -

Catherine Hanna,

Kathreena M. Kurian,

Karin Williams,

Colin Watts,

Alan Jackson,

Ross Carruthers,

Karen Strathdee,

Garth Cruickshank,

Laurence Dunn,

Sara Erridge,

Lisa Godfrey,

Sarah Jefferies,

Catherine McBain,

Rebecca Sleigh,

Alex McCormick,

Marc Pittman,

Sarah Halford,

Anthony J. Chalmers

Publication year - 2020

Publication title -

neuro-oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.005

H-Index - 125

eISSN - 1523-5866

pISSN - 1522-8517

DOI - 10.1093/neuonc/noaa104

Subject(s) - olaparib , tolerability , medicine , temozolomide , parp inhibitor , oncology , pharmacokinetics , pharmacology , cancer research , chemotherapy , adverse effect , poly adp ribose polymerase , chemistry , biochemistry , polymerase , gene

The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide (TMZ) chemotherapy in preclinical glioblastoma models but brain penetration was poor. Clinically, PARP inhibitors exacerbate the hematological side effects of TMZ. The OPARATIC trial was conducted to measure penetration of recurrent glioblastoma by olaparib and assess the safety and tolerability of its combination with TMZ.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research